Failed 2024

    Jianke

    Pure-play startups cannot compete with tech giants in winner-take-most markets without significant 'unfair advantages' like regulatory relationships or existing user bases.

    TL;DR — Failure Post-Mortem

    Jianke was a Health Care/Marketplace startup founded in 2011 in China. It raised $150M before collapsing in 2024 — 13 years of runway burned. IdeaProof's AI Failure Score: 0/100, driven by competitive asphyxiation in crowded market. The shutdown affected employees, investors, and the broader Health Care/Marketplace ecosystem. This case study breaks down the timeline, root causes, competitors that won, and replicable lessons for founders validating similar ideas today.

    Why did Jianke fail?

    Jianke failed in 2024 after 13 years of operation, losing $150M in raised capital. The root cause was competitive asphyxiation in crowded market. Key lesson: Pure-play startups cannot compete with tech giants in winner-take-most markets without significant 'unfair advantages' like regulatory relationships or existing user bases.

    Verifiable facts
    Sourced
    Founded → Closed

    2011 → 2024

    Funding Raised

    $150M

    Industry

    Health Care/Marketplace

    Country

    China

    Causal Chain

    Derived · heuristic

    This is our reading of the causal chain — separated from the verifiable facts above. Timeline dates, funding numbers and filings are facts (see methodology); root / proximate / terminal attribution is judgement based on public evidence.

    Root cause

    A combination of demand-side, execution, and capital-market pressures that this record documents without isolating a single dominant driver.

    Contributing factors
    • Sector context: Health Care/Marketplace in China, 13 years of runway.
    Terminal event

    2024: cessation of operations after failing to secure additional capital or a strategic buyer.

    Base rates

    External sources

    A single failure is an anecdote. These base rates give you the denominator — how common this outcome is across all startups matching Jianke's profile. Sources are third-party; we do not restate them as our own claims.

    ~70%
    industry

    of digital-health startups fail to reach breakeven; reimbursement complexity + regulatory approvals extend runway needs beyond typical VC horizons.

    Rock Health State of Digital Health (2023)
    ~90%
    all

    of startups ultimately fail — including ~10% that fail in the first year and the rest across the following decade.

    Startup Genome / CB Insights aggregate (2024)
    ~35%
    all

    of new US employer businesses survive past their 10th year (Bureau of Labor Statistics BED series).

    US Bureau of Labor Statistics — BED (2024)
    ~35%
    stage

    of Series A rounds ever graduate to Series B; the rest run out of runway or pivot without a follow-on.

    CB Insights Venture Capital Funnel (2023)

    Full Analysis

    Jianke, a Chinese online healthcare platform founded in 2011, aimed to create an integrated ecosystem of patients, doctors, pharmacies, and healthcare services. It successfully raised $150M to tackle China's massive healthcare accessibility issues by offering online consultations, prescription fulfillment, and e-pharmacy services. The company operated in a rapidly growing digital landscape with increasing internet and smartphone adoption, and emerging telemedicine regulations. However, Jianke entered a market that quickly became dominated by tech giants like Alibaba Health, JD Health, Ping An Good Doctor, and WeDoctor. These dominant players had significantly deeper pockets, stronger ecosystem integrations, and better regulatory relationships, which Jianke lacked. The primary reason for Jianke's failure was competitive asphyxiation. It struggled to differentiate its offerings in a market that rapidly consolidated around a few well-funded and established players. Jianke's 'horizontal marketplace' model, which aimed to be a one-stop shop, was directly challenged by competitors who built similar platforms with massive resources and advantages. The company did not possess an 'unfair advantage'—such as a large existing user base, strong government ties, or proprietary logistics infrastructure—that would have enabled it to withstand the fierce competition. Its business model required significant investment in network acquisition and regulatory compliance, making it difficult to scale efficiently against well-entrenched competitors. Key lessons from Jianke's demise include the importance of differentiation and strategic assets in highly competitive, winner-take-most markets, especially in regulated industries like healthcare. For startups, simply having a good product is often insufficient when competing against platform companies with vast resources. Success demands a clear competitive moat, whether it's through niche specialization, proprietary technology, strong political connections, or leveraging an existing ecosystem. Without these, even well-funded startups can be squeezed out by larger, more powerful players who are able to outspend and outmaneuver them, ultimately leading to failure.

    Frequently Asked Questions

    Could This Failure Have Been Prevented?

    IdeaProof's AI validates market demand, competitive positioning, and business model viability in minutes — catching the exact issues that sank Jianke.

    Related Failures

    HomeHero

    $23M · 2017

    Misunderstood healthcare economics & regulations

    Spotted a factual error?

    Approved corrections are published in the public changelog with attribution.

    After Jianke: hubs, comparisons and deep dives

    Compare the validation, funding and go-to-market choices that separate survivors from failures like Jianke.